Answers are grounded in this paper and cite their sources.
Background: Amikacin (AK) may adversely affect male reproductive tissues. This study investigated whether misoprostol (MP) protects against AK-induced testicular injury, focusing on endocrine function, spermatogenesis, Peroxisome proliferator-activated receptor alpha (PPARα) mRNA expression, and apoptosis- and inflammation-associated markers. Methods: Twenty-four male Sprague–Dawley rats were randomized into control, AK, MP, and AK+MP groups (n = 6). MP (0.2 mg/kg/day) was administered orally for six days, and AK (1.2 g/kg) intraperitoneally on day 3. Serum testosterone, testicular PPARα mRNA, histopathology, Johnsen scores, and Caspase-8 and NF-κB immunoreactivity were evaluated. Results: AK significantly reduced testosterone, PPARα mRNA expression (vs. control, p < 0.05), and Johnsen scores, increased Caspase-8 and NF-κB immunoreactivity, and caused seminiferous tubular damage. Compared with AK alone, MP co-treatment significantly increased testosterone concentrations and PPARα mRNA expression (p < 0.0001), reduced histopathological damage and both immunoreactivity markers, and partially preserved spermatogenesis. Complete recovery was not achieved. PPARα mRNA expression was also significantly higher in the MP-only group than in controls. Conclusions: MP attenuated AK-induced testicular injury, accompanied by improved endocrine and spermatogenic parameters, altered PPARα mRNA expression, and reduced Caspase-8 and NF-κB immunoreactivity. Further studies are needed to clarify the underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Özgöçmen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: